Yoshihiko Yano

19PUBLICATIONS
39CO-AUTHORS
Biomedical imagingHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Mar 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima

|Nov 18, 2025
Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis.

Tatsuya Sakane, Toshifumi Tada, Hiroshi Tei

|Jun 04, 2025
Utility of gel filtration chromatography in evaluating successful resection of ectopic adrenocorticotropic hormone-producing tumor: a case report and literature review.

Mei Nakatsuji, Hironori Bando, Masaaki Yamamoto

|Apr 04, 2025
Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor-Induced Liver Injury Types.

Jun Kitadai, Toshifumi Tada, Takanori Matsuura

|Feb 24, 2025
Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma.

Yuta Inoue, Yoshihiko Yano, Saeko Kushida

|Apr 26, 2024
Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.

Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto

Pageof 4

Frequent Collaborators

2 joint publications

Yoshihide Ueda

2 joint publications

Kandai Nozu

2 joint publications

Yasuhiro Takeshima

2 joint publications

Tomoko Lee